Regeneron shares slump after results badly miss estimates

7 May 2019
regeneron-location-big

US biotech Regeneron (Nasdaq: REGN) missed the expectations of Wall Street analysts in both its first-quarter sales and earnings, sending its share price tumbling on Tuesday.

Total revenue rose by 13% compared to the first quarter of 2018, to $1.71 billion, but this was still well shy of the FactSet consensus of $1.77 billion.

Profit for the latest quarter fell to $461 million from $478 million a year ago, a 4% decline, and adjusted earnings per share came in at $4.45 per share, badly missing the FactSet consensus of $5.48 per share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology